This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ clebopride maleate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastrointestinal Disorders: Clebopride maleate has historically been used to treat various gastrointestinal conditions characterized by abnormalities in gastrointestinal motility, including functional dyspepsia, gastroesophageal reflux disease (GERD), gastroparesis, and non-ulcer dyspepsia. It works by stimulating gastrointestinal motility and accelerating gastric emptying, thereby reducing symptoms such as bloating, nausea, vomiting, early satiety, and abdominal discomfort.

  2. Prokinetic Agent: Clebopride maleate belongs to a class of medications known as prokinetic agents, which exert their effects by enhancing the coordination and strength of contractions in the gastrointestinal tract. By stimulating the release of acetylcholine and inhibiting the reuptake of serotonin, clebopride maleate promotes smooth muscle contraction in the stomach and intestines, leading to improved gastrointestinal motility and transit.

  3. Antiemetic: In addition to its prokinetic effects, clebopride maleate also has antiemetic properties and may be used to prevent or alleviate nausea and vomiting associated with various gastrointestinal disorders, chemotherapy, or postoperative recovery. By acting on dopamine receptors in the chemoreceptor trigger zone (CTZ) of the brainstem, clebopride maleate helps suppress nausea and vomiting signals, thereby reducing symptoms and improving patient comfort.

  4. Safety Concerns: Despite its efficacy in promoting gastrointestinal motility and relieving symptoms of gastrointestinal disorders, the use of clebopride maleate has been limited due to safety concerns, particularly its potential to cause cardiac arrhythmias, including QT interval prolongation and torsades de pointes. These cardiac effects are primarily associated with high doses of clebopride maleate or its long-term use and may increase the risk of serious adverse cardiovascular events, including sudden cardiac death.

  5. Regulatory Status: Clebopride maleate is not approved for medical use in many countries, including the United States, due to safety concerns. In countries where it was previously available, its use has been restricted or discontinued, and alternative medications with better safety profiles are now preferred for the treatment of gastrointestinal disorders.

  6. Drug Interactions: Clebopride maleate may interact with other medications that prolong the QT interval or affect cardiac conduction, such as certain antibiotics, antifungal agents, antidepressants, and antipsychotic drugs. Concurrent use of clebopride maleate with these medications may increase the risk of QT interval prolongation and cardiac arrhythmias.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of clebopride maleate,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by clebopride maleate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Phocaeicola genus Decreases
0 1 Clostridium genus Decreases
0 1 Fusobacterium genus Decreases
0 1 Segatella genus Decreases
0 1 Bacteroides genus Decreases
0 1 Agathobacter genus Decreases
0 1 Roseburia genus Decreases
0 1 Streptococcus genus Decreases
0 1 Lacticaseibacillus genus Decreases
1 0 Akkermansia genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Escherichia genus Decreases
0 1 Bifidobacterium genus Decreases
0 1 Clostridioides genus Decreases
0 1 Bilophila genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
0 1 Escherichia coli O1:K1:H7 no rank Decreases
0 1 Escherichia coli O139:H1 no rank Decreases
0 1 Escherichia coli O141:H4 no rank Decreases
0 1 Escherichia coli O145:H34 no rank Decreases
0 1 Escherichia coli O15:H12 no rank Decreases
0 1 Escherichia coli O155:H21 no rank Decreases
0 1 Escherichia coli O158:H23 no rank Decreases
0 1 Escherichia coli O16:H48 no rank Decreases
0 1 Escherichia coli O170:H18 no rank Decreases
0 1 Escherichia coli O18ac:H14 no rank Decreases
0 1 Escherichia coli O19:H7 no rank Decreases
0 1 Escherichia coli O2:K1:H4 no rank Decreases
0 1 Escherichia coli O2:K1:H5 no rank Decreases
0 1 Escherichia coli O2:K1:H7 no rank Decreases
0 1 Escherichia coli O20:H12 no rank Decreases
0 1 Escherichia coli O25:H16 no rank Decreases
0 1 Escherichia coli O55:H7 no rank Decreases
0 1 Escherichia coli O68:H12 no rank Decreases
0 1 Escherichia coli O7:H15 no rank Decreases
0 1 Escherichia coli O78:H51 no rank Decreases
0 1 Escherichia coli O80:H26 no rank Decreases
0 1 Escherichia coli O84:H7 no rank Decreases
0 1 Escherichia coli O85:H1 no rank Decreases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
0 1 Escherichia coli O103 serogroup Decreases
0 1 Escherichia coli O111 serogroup Decreases
0 1 Escherichia coli O119 serogroup Decreases
0 1 Escherichia coli O121 serogroup Decreases
0 1 Escherichia coli O145 serogroup Decreases
0 1 Escherichia coli O155 serogroup Decreases
0 1 Escherichia coli O157 serogroup Decreases
0 1 Escherichia coli O177 serogroup Decreases
0 1 Escherichia coli O26 serogroup Decreases
0 1 Escherichia coli O3 serogroup Decreases
0 1 Escherichia coli O43 serogroup Decreases
0 1 Escherichia coli O5 serogroup Decreases
0 1 Escherichia coli O78 serogroup Decreases
0 1 Escherichia coli O86 serogroup Decreases
0 1 Escherichia coli O91 serogroup Decreases
0 1 Escherichia coli H20 serotype Decreases
0 1 Escherichia coli O1:H42 serotype Decreases
0 1 Escherichia coli O1:HNT serotype Decreases
0 1 Escherichia coli O10:H32 serotype Decreases
0 1 Escherichia coli O10:K5(L):H4 serotype Decreases
0 1 Escherichia coli O100:H21 serotype Decreases
0 1 Escherichia coli O103:H11 serotype Decreases
0 1 Escherichia coli O103:H2 serotype Decreases
0 1 Escherichia coli O103:H25 serotype Decreases
0 1 Escherichia coli O104:H21 serotype Decreases
0 1 Escherichia coli O104:H4 serotype Decreases
0 1 Escherichia coli O111:H- serotype Decreases
0 1 Escherichia coli O111:H11 serotype Decreases
0 1 Escherichia coli O111:H8 serotype Decreases
0 1 Escherichia coli O111:NM serotype Decreases
0 1 Escherichia coli O112ab:H8 serotype Decreases
0 1 Escherichia coli O112ac:H19 serotype Decreases
0 1 Escherichia coli O113:H21 serotype Decreases
0 1 Escherichia coli O114:H49 serotype Decreases
0 1 Escherichia coli O118:H16 serotype Decreases
0 1 Escherichia coli O121:H19 serotype Decreases
0 1 Escherichia coli O121:H7 serotype Decreases
0 1 Escherichia coli O123:H11 serotype Decreases
0 1 Escherichia coli O125ac:K+:H10 serotype Decreases
0 1 Escherichia coli O126:H45 serotype Decreases
0 1 Escherichia coli O127:H27 serotype Decreases
0 1 Escherichia coli O127:H6 serotype Decreases
0 1 Escherichia coli O128:H2 serotype Decreases
0 1 Escherichia coli O128ac:H12 serotype Decreases
0 1 Escherichia coli O139:H28 serotype Decreases
0 1 Escherichia coli O145:H25 serotype Decreases
0 1 Escherichia coli O145:H28 serotype Decreases
0 1 Escherichia coli O145:NM serotype Decreases
0 1 Escherichia coli O146:H21 serotype Decreases
0 1 Escherichia coli O15:H18 serotype Decreases
0 1 Escherichia coli O150:H6 serotype Decreases
0 1 Escherichia coli O152:H23 serotype Decreases
0 1 Escherichia coli O153:H2 serotype Decreases
0 1 Escherichia coli O156:H25 serotype Decreases
0 1 Escherichia coli O157:H- serotype Decreases
0 1 Escherichia coli O157:H43 serotype Decreases
0 1 Escherichia coli O157:H7 serotype Decreases
0 1 Escherichia coli O157:NM serotype Decreases
0 1 Escherichia coli O16:H6 serotype Decreases
0 1 Escherichia coli O165:H25 serotype Decreases
0 1 Escherichia coli O167:H26 serotype Decreases
0 1 Escherichia coli O174:H2 serotype Decreases
0 1 Escherichia coli O174:H21 serotype Decreases
0 1 Escherichia coli O174:H8 serotype Decreases
0 1 Escherichia coli O176:H45 serotype Decreases
0 1 Escherichia coli O177:NM serotype Decreases
0 1 Escherichia coli O2:H6 serotype Decreases
0 1 Escherichia coli O2:K2:H1 serotype Decreases
0 1 Escherichia coli O25:H1 serotype Decreases
0 1 Escherichia coli O25:NM serotype Decreases
0 1 Escherichia coli O26:H1 serotype Decreases
0 1 Escherichia coli O26:H11 serotype Decreases
0 1 Escherichia coli O28ac:NM serotype Decreases
0 1 Escherichia coli O29:H4 serotype Decreases
0 1 Escherichia coli O32:H37 serotype Decreases
0 1 Escherichia coli O39:NM serotype Decreases
0 1 Escherichia coli O44:H18 serotype Decreases
0 1 Escherichia coli O45:H2 serotype Decreases
0 1 Escherichia coli O6:H16 serotype Decreases
0 1 Escherichia coli O6:H16:CFA/II serotype Decreases
0 1 Escherichia coli O6:K2:H1 serotype Decreases
0 1 Escherichia coli O69:H11 serotype Decreases
0 1 Escherichia coli O7:H4 serotype Decreases
0 1 Escherichia coli O7:K1 serotype Decreases
0 1 Escherichia coli O78:H12 serotype Decreases
0 1 Escherichia coli O78:H4 serotype Decreases
0 1 Escherichia coli O79:H7 serotype Decreases
0 1 Escherichia coli O8:H8 serotype Decreases
0 1 Escherichia coli O81:NM serotype Decreases
0 1 Escherichia coli O83:H1 serotype Decreases
0 1 Escherichia coli O86:H34 serotype Decreases
0 1 Escherichia coli O89m:H10 serotype Decreases
0 1 Escherichia coli O89m:H9 serotype Decreases
0 1 Escherichia coli O9:H10 serotype Decreases
0 1 Escherichia coli O91:H14 serotype Decreases
0 1 Escherichia coli O91:NM serotype Decreases
0 1 Escherichia coli O99:H6 serotype Decreases
0 1 Escherichia coli ONT:H33 serotype Decreases
1 0 Clostridium perfringens species Decreases
1 0 Fusobacterium nucleatum species Decreases
1 0 Bacteroides ovatus species Decreases
1 0 Bacteroides uniformis species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Segatella copri species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Streptococcus parasanguinis species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Akkermansia muciniphila species Decreases
1 0 Mediterraneibacter gnavus species Decreases
0 1 Streptococcus sp. HSISM1 species Decreases
0 1 Bacteroides humanifaecis species Decreases
0 1 Streptococcus sp. LPB0220 species Decreases
1 0 Escherichia coli species Decreases
0 1 Roseburia rectibacter species Decreases
0 1 Bacteroides sp. D2 species Decreases
0 1 Bacteroides sp. CACC 737 species Decreases
0 1 Bacteroides sp. DH3716P species Decreases
0 1 Segatella bryantii species Decreases
0 1 Bacteroides sp. M10 species Decreases
0 1 Bacteroides luhongzhouii species Decreases
1 0 Bifidobacterium adolescentis species Decreases
1 0 Clostridioides difficile species Decreases
0 1 Leyella stercorea species Decreases
0 1 Bacteroides sp. A1C1 species Decreases
0 1 Bacteroides sp. HF-162 species Decreases
0 1 Pseudobutyrivibrio xylanivorans species Decreases
0 1 Bacteroides faecium species Decreases
0 1 Shigella dysenteriae species Decreases
1 0 Bilophila wadsworthia species Decreases
0 1 Shigella flexneri species Decreases
0 1 Prevotella intermedia species Decreases
0 1 Streptococcus lactarius species Decreases
0 1 Escherichia albertii species Decreases
0 1 Bacteroides caecimuris species Decreases
0 1 Bacteroides xylanisolvens species Decreases
0 1 Streptococcus gordonii species Decreases
0 1 Leyella lascolaii species Decreases
0 1 Lachnospira eligens species Decreases
0 1 Escherichia fergusonii species Decreases
0 1 Bifidobacterium angulatum species Decreases
0 1 Streptococcus salivarius species Decreases
1 0 Parabacteroides merdae species Decreases
0 1 Simiaoa sunii species Decreases
0 1 Paraprevotella clara species Decreases
0 1 Prevotella bivia species Decreases
0 1 Butyrivibrio crossotus species Decreases
0 1 Intestinibaculum porci species Decreases
0 1 Streptococcus sp. FDAARGOS_192 species Decreases
0 1 Wujia chipingensis species Decreases
0 1 Streptococcus australis species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
1 0 Bacteroides caccae species Decreases
0 1 Fusobacterium nucleatum subsp. nucleatum subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of clebopride maleate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0.1 -0.1
ADHD 2.4 2.4
Age-Related Macular Degeneration and Glaucoma 0.2 0.1 1
Allergic Rhinitis (Hay Fever) 1.3 1.3 0
Allergies 1.9 2.2 -0.16
Allergy to milk products 1.1 0.5 1.2
Alzheimer's disease 4 2.6 0.54
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1.2 0.6 1
Ankylosing spondylitis 1.6 0.8 1
Anorexia Nervosa 0.6 1.5 -1.5
Antiphospholipid syndrome (APS) 0.8 0.1 7
Asthma 2.2 1.4 0.57
Atherosclerosis 1.4 1 0.4
Atrial fibrillation 1.1 1.5 -0.36
Autism 4.6 4.5 0.02
Autoimmune Disease 0.4 0.6 -0.5
Barrett esophagus cancer 0.3 0.2 0.5
benign prostatic hyperplasia 0.1 0.2 -1
Biofilm 1.7 1.7
Bipolar Disorder 0.8 0.2 3
Brain Trauma 0.3 0.5 -0.67
Breast Cancer 0.9 0.9
Cancer (General) 0.3 1.2 -3
Carcinoma 1.7 0.4 3.25
Celiac Disease 2.1 0.6 2.5
Cerebral Palsy 1 0.4 1.5
Chronic Fatigue Syndrome 3.1 1.7 0.82
Chronic Kidney Disease 1 0.9 0.11
Chronic Lyme 0.2 0.4 -1
Chronic Obstructive Pulmonary Disease (COPD) 1.2 0.7 0.71
Chronic Urticaria (Hives) 0.9 1.2 -0.33
Coagulation / Micro clot triggering bacteria 0.6 0.4 0.5
Cognitive Function 0.6 0.8 -0.33
Colorectal Cancer 4.8 1.7 1.82
Constipation 1 0.2 4
Coronary artery disease 1.1 1.2 -0.09
COVID-19 4.1 5.2 -0.27
Crohn's Disease 4.7 2.2 1.14
Cushing's Syndrome (hypercortisolism) 0.8 -0.8
cystic fibrosis 0.4 0.7 -0.75
d-lactic acidosis (one form of brain fog) 0.3 0.3
deep vein thrombosis 1.5 0.6 1.5
Denture Wearers Oral Shifts 0.9 0.9
Depression 4.7 3.1 0.52
Dermatomyositis 0.2 0.1 1
Eczema 1.2 1.3 -0.08
Endometriosis 1.1 0.4 1.75
Eosinophilic Esophagitis 0.3 0.2 0.5
Epilepsy 2.4 0.9 1.67
erectile dysfunction 1 0.1 9
Fibromyalgia 0.8 1.8 -1.25
Functional constipation / chronic idiopathic constipation 3.2 2 0.6
gallstone disease (gsd) 1.4 0.7 1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.9 0.2 8.5
Generalized anxiety disorder 1.6 1 0.6
giant cell arteritis 0.3 -0.3
Glioblastoma 0.2 -0.2
Gout 0.7 0.5 0.4
Graves' disease 0.4 0.7 -0.75
Gulf War Syndrome 0.5 0.9 -0.8
Halitosis 1.3 0.2 5.5
Hashimoto's thyroiditis 1.4 0.5 1.8
Heart Failure 2.4 0.8 2
hemorrhagic stroke 0.4 0.4
Hidradenitis Suppurativa 0.8 0.8
High Histamine/low DAO 1.4 0.1 13
hypercholesterolemia (High Cholesterol) 0.6 0.3 1
hyperglycemia 0.7 0.8 -0.14
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 1.3 1.6 -0.23
Hypothyroidism 0.3 0.1 2
Hypoxia 1.5 1.5
IgA nephropathy (IgAN) 0.8 2.9 -2.62
Inflammatory Bowel Disease 5.3 4.3 0.23
Insomnia 0.5 1.4 -1.8
Intelligence 1.4 0.6 1.33
Intracranial aneurysms 0.7 0.7
Irritable Bowel Syndrome 2.9 3.4 -0.17
ischemic stroke 0.8 0.7 0.14
Liver Cirrhosis 2.7 2.2 0.23
Long COVID 2.3 1.6 0.44
Low bone mineral density 0.2 -0.2
Lung Cancer 0.2 0.3 -0.5
Lymphoma 0.1 0.1
Mast Cell Issues / mastitis 0.9 0.1 8
ME/CFS with IBS 0.5 0.3 0.67
ME/CFS without IBS 0.8 0.3 1.67
membranous nephropathy 0.2 0.2
Menopause 1 0.3 2.33
Metabolic Syndrome 2.8 3.7 -0.32
Mood Disorders 4.7 2.7 0.74
multiple chemical sensitivity [MCS] 0.4 0.4
Multiple Sclerosis 3.3 3.1 0.06
Multiple system atrophy (MSA) 0.8 0.1 7
myasthenia gravis 0.3 0.5 -0.67
neuropathic pain 0.6 -0.6
Neuropathy (all types) 0.3 0.4 -0.33
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.8 1.6 0.75
NonCeliac Gluten Sensitivity 0.6 0.3 1
Obesity 3.3 3.9 -0.18
obsessive-compulsive disorder 3.2 1.9 0.68
Osteoarthritis 1.8 0.7 1.57
Osteoporosis 0.9 0.7 0.29
pancreatic cancer 0.8 0.2 3
Parkinson's Disease 2.8 3.3 -0.18
Polycystic ovary syndrome 2.9 1.2 1.42
Postural orthostatic tachycardia syndrome 0.3 0.1 2
Premenstrual dysphoric disorder 0.1 0.1 0
primary biliary cholangitis 0.2 1.4 -6
Primary sclerosing cholangitis 1.4 0.7 1
Psoriasis 1.4 1.7 -0.21
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.6 1.9 0.37
Rosacea 0.1 0.5 -4
Schizophrenia 3 1 2
scoliosis 0.3 0.2 0.5
Sjögren syndrome 0.9 1.4 -0.56
Sleep Apnea 0.4 0.4 0
Slow gastric motility / Gastroparesis 0.5 0.1 4
Small Intestinal Bacterial Overgrowth (SIBO) 1.3 1.3
Stress / posttraumatic stress disorder 1.6 0.9 0.78
Systemic Lupus Erythematosus 2 0.3 5.67
Tic Disorder 0.8 0.8 0
Tourette syndrome 0.3 0.2 0.5
Type 1 Diabetes 2.8 1.8 0.56
Type 2 Diabetes 3.7 4 -0.08
Ulcerative colitis 3.7 4.3 -0.16
Unhealthy Ageing 2.9 0.9 2.22
Vitiligo 0.9 0.6 0.5

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]